Waters Corporation (Milford, Massachusetts) entered into an agreement with the Chinese Pharmacopoeia Commission (ChP) to establish a joint open laboratory.
Waters Corporation (Milford, Massachusetts) entered into an agreement with the Chinese Pharmacopoeia Commission (ChP) to establish a joint open laboratory. Scheduled to open before the end of 2014, the laboratory will focus on in-depth research of pharmacopoeia standards, development of testing methods, method validation, and basic and advanced technical training of pharmacopoeia detection methods. Both the ChP and Waters expect the laboratory to become one of the national technical support centers in Chinese pharmaceutical standards.
The Joint Open Laboratory will be located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute (Beijing, China) and will be more than 1300 square feet in size. It will be outfitted with Waters’ chromatography and mass spectrometry systems, including, but not limited to, a range of Acquity UPLC systems, Acquity UPC2 systems, Xevo tandem quadrupole and time-of-flight mass spectrometers, and a natural products application solution with UNIFI software.
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.